We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Read MoreHide Full Article
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) closed at $8.58, marking a -8.43% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.76%. At the same time, the Dow lost 0.68%, and the tech-heavy Nasdaq lost 1.13%.
The company's stock has climbed by 24.27% in the past month, exceeding the Medical sector's loss of 3.03% and the S&P 500's gain of 1.26%.
The upcoming earnings release of Ginkgo Bioworks Holdings, Inc. will be of great interest to investors. In that report, analysts expect Ginkgo Bioworks Holdings, Inc. to post earnings of -$0.58 per share. This would mark year-over-year growth of 60%. At the same time, our most recent consensus estimate is projecting a revenue of $20.5 million, reflecting a 47.22% fall from the equivalent quarter last year.
DNA's full-year Zacks Consensus Estimates are calling for earnings of -$3.2 per share and revenue of $82.2 million. These results would represent year-over-year changes of +43.26% and -51.69%, respectively.
Investors might also notice recent changes to analyst estimates for Ginkgo Bioworks Holdings, Inc. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Ginkgo Bioworks Holdings, Inc. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 172, putting it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) closed at $8.58, marking a -8.43% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.76%. At the same time, the Dow lost 0.68%, and the tech-heavy Nasdaq lost 1.13%.
The company's stock has climbed by 24.27% in the past month, exceeding the Medical sector's loss of 3.03% and the S&P 500's gain of 1.26%.
The upcoming earnings release of Ginkgo Bioworks Holdings, Inc. will be of great interest to investors. In that report, analysts expect Ginkgo Bioworks Holdings, Inc. to post earnings of -$0.58 per share. This would mark year-over-year growth of 60%. At the same time, our most recent consensus estimate is projecting a revenue of $20.5 million, reflecting a 47.22% fall from the equivalent quarter last year.
DNA's full-year Zacks Consensus Estimates are calling for earnings of -$3.2 per share and revenue of $82.2 million. These results would represent year-over-year changes of +43.26% and -51.69%, respectively.
Investors might also notice recent changes to analyst estimates for Ginkgo Bioworks Holdings, Inc. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Ginkgo Bioworks Holdings, Inc. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 172, putting it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.